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BACKGROUND Catheter-based renal artery denervation therapy has
become established as a therapeutic option in patients with resistant
hypertension. We further investigated the safety and performance of
the next generation EnligHTN Renal Denervation System (St. Jude
Medical) in patients with drug-resistant hypertension.
METHODS The EnligHTN Renal Artery Ablation Catheter has 4
electrodes attached on a basket mounted at the tip of the catheter.
The basket is collapsed and can be expanded via an external mecha-
nism once the catheter is placed in the desired location of the renal
artery. The next generation EnligHTN RF Ablation Generator
utilizes a novel algorithm for the delivery of 1 minute of radio-
frequency energy, optimized for simultaneous delivery of therapy
through all 4 electrodes, with an interactive, intuitive user interface.
Renal denervation was performed on 39 patients across 6 centers
meeting the following inclusion criteria: 18-80 years of age, a
systolic BP 160 mmHg, an average daytime systolic ambulatory
BP 135 mmHg, on three or more antihypertensive agents (including a
diuretic), and renal artery diameter 4mm and length 20mm. The
primary endpoints are 1) to characterize the rate of serious procedural
and device related adverse events from date of procedure through 6
months post procedure and 2) the change in ofﬁce BP at 6 months post
procedure. The secondary endpoints include the changes in 24 hour
ambulatory BP and the characterization of renovascular safety and
renal function change over time from baseline. Renal artery CT angi-
ography was repeated at 6 months in all patients. The multi-electrode
ablation catheter was introduced into each renal artery and two sets of
denervation therapy delivered per renal artery.
RESULTS To date 37/38 patients have completed 18-months of follow-
up post procedure. One serious device or procedure related adverse
event, a pseudo aneurysm, has been observed as adjudicated by an
independent Clinical Events Committee. There were no clinically
signiﬁcant changes in renal function through 18-months as observed
in eGFR, serum creatinine, cystatin C, or urine albumin-to-creatinine
ratio. 18-month ofﬁce (and 12M, 24 hour ambulatory) BP reductions
from baseline were -25/-8 (-11/-4) mmHg, which were statistically
signiﬁcant except for the ambulatory diastolic reduction. Renal artery
denervation procedures were performed successfully in all patients,
with an average of 4.33 ablation sets and 15.85 ablations performed
per patient. The mean total ablation catheter insertion-to-removal
time was 22.38 min and mean ablation time was 4.33 min per patient.
CONCLUSIONS Accumulated 24-month results from all sites will be
presented at the meeting. After 18-months follow-up post procedure
in this ﬁrst-in-human study, we conclude that data demonstrates the
next generation EnligHTN Renal Denervation System continues to be
safe, rapid, and effective in the treatment of patients with drug-
resistant, uncontrolled hypertension.
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BACKGROUND The Kona Medical Surround Sound System is a non-
invasive device for renal denervation that delivers externally focused
ultrasound to the renal nerves using Doppler-based image guidance to
track and correct for renal artery motion during the procedure. Aims:
To evaluate the safety and efﬁcacy of an entirely non-invasive
approach to renal denervation using externally delivered focused ul-
trasound with real time Doppler-based image guidance in treatment
resistant hypertension (TRH).
METHODS In 3 consecutive studies 69 patients with severe TRH,
deﬁned as persistent systolic blood pressure (BP) > 160 mmHg
despite 3 or more antihypertensive medications, were treated non-
invasively with the Kona Medical Surround Sound System. Focused
ultrasound energy was delivered to the renal arteries bilaterally and
surrounding tissue using Doppler-based imaging and continuous
tracking with automatic correction for kidney motion throughout
treatment. Patients received conscious sedation during the treatment
period.
RESULTS At this time, all patients have completed 24 weeks
follow-up and 61 patients have completed 52 weeks of follow-up.
Post-denervation, the mean changes from baseline BP were -16.2/-
6.7 mmHg at 3 weeks, -22.3/-9.0 mmHg at 6 weeks, -24,4/-9.9 mmHg
at 12 weeks, -24.6/-9.0 mmHg at 24 weeks and -22.9/-9.9 mmHg 52
weeks . Response rates (drop in BP by > 10 mmHg) was 75% at 6
and 12 months. No serious intervention related events have been
reported to date. Forty-six percent of subjects (32/69) reported mild
back pain immediately following the denervation treatment. The
majority of cases (19/32) completely resolved within seven days post
treatment and no case was associated with any motor, sensory
deﬁcits.
CONCLUSIONS This is the ﬁrst data in humans using a non-invasive
renal denervation system in severe TRH. Results showed clinically
meaningful reductions in ofﬁce BP through 52 weeks post-denerva-
tion. The procedure was well-tolerated with no serious adverse
events. Sham-operator controlled studies with the Kona systems to
evaluate the safety and efﬁcacy of this novel non-invasive treatment
are in the recruiting and planning stages.
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BACKGROUND Despite recent setbacks and limitations with radio-
frequency (RF)-based therapies, there is continued interest in
renal denervation as a therapy for uncontrolled hypertension. We
present an update of targeted “chemical renal denervation” using
alcohol as the neurolytic agent, as an alternative method for renal
denervation.
METHODS The Peregrine System is a novel endovascular catheter
with three micro-needles which are deployed into the perivascular
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to directly target the nerves. Alcohol is administered using a single
infusion in the main renal artery. Doses of 0.15 to 0.6 mL have been
studied in this model. The denervation produced with alcohol has
been characterized with histology, immunostaining and measurement
of renal norepinephrine (NE) in a porcine model. A direct comparison
of the denervation produced with alcohol vs. RF was performed using
the same model and methods (3 mos. survival). For the RF group 4
renal artery ablations were performed, with one ablation per
quadrant.
RESULTS Renal denervation with alcohol creates consistent, dose-
related and substantial sympathetic nerve injury. The Peregrine
catheter delivers the alcohol directly within the adventitia and peri-
adventitial space. Because the alcohol is infused outside of the vessel
wall, changes to the media are rare; typically mild and focal; and at
the abluminal surface of the media. This contrasts with RF, which
typically creates focal transmural medial injury. The ablation area
produced by the infusion of alcohol is larger, and typically circum-
ferential, in comparison to the focal ablation produced by RF. Ablation
depth (distance from the lumen) and area (morphometric) were
signiﬁcantly greater for alcohol using 0.3 mL and 0.6 mL per artery,
compared to RF. Depth (p<0.05 for both alcohol doses) compared to
RF: 0.3 mL ¼ 6.61.2 mm, 0.6 mL ¼ 8.22.2 mm, RF ¼ 3.91.2 mm.
Area (p¼0.0001): 0.3 mL ¼ 30.813.7 mm2, 0.6 mL ¼ 41.67.5 mm2,
RF ¼ 11.07.5 mm2. Compared to controls the median NE was reduced
by 83% for 0.6 mL, 76% for 0.3 mL and 66% for RF (p¼0.095 both
alcohol vs. RF). The median procedure time for the alcohol groups was
9 min. vs. 29 min. for RF (p<0.05). Neither RF nor alcohol infusion
produced any systemic or renal adverse events.
CONCLUSIONS The use of alcohol with the Peregrine System for
“chemical” renal denervation appears to be potentially safer and more
time efﬁcient than RF. Alcohol-mediated denervation appears to
address the issue of adequacy of denervation by demonstrating su-
perior coverage in terms of ablation depth and area, yielding a greater
reduction in renal NE vs. RF. Chemical denervation can also be per-
formed in very short renal arteries, avoiding technical issues and
adverse events associated with treating the entire length of the artery,
or the distal branches as has been proposed for RF. Overall, chemical
denervation using alcohol may represent a promising alternative to
RF ablation.
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BACKGROUND Renal denervation (RDN) for the treatment of
resistant hypertension has been shown in pilot studies to lower blood
pressure (BP) without safety alerts. However, this was only shown in
open la-belled study designs and has primarily addressed the effect
on ofﬁce BP. We therefore conducted a sham controlled, double
blind randomized single center trial to establish reliable efﬁcacy
data based on 24-h BP measurements. We expected a 10 mmHg
reduction in ABPM systolic daytime BP (ASBP-day) at 3 months in the
RDN group as compared to SHAM, and planned to randomize 70
patients.
METHODS Patients with therapy resistant essential hypertension, 30
to 70 years of age, were randomly as-signed to undergo RDN or a sham
procedure. Inclusion criteria were ASBP-day  145 mmHg follow one
month of stable medication and 2 weeks of compliance registration.Recruitment and patient follow-up was held in seven dedicated hy-
pertension out-patient clinics. Drug treatment was optional, apart
from the mandatory use of a diuretic when tolerated by the
patient. Follow-up changes in antihypertensive medication were
only allowed if requested by the patient or if harm-full changes in
BP or safety parameters occurred. Renal artery anatomy was evalu-
ated by CT angio in advance. All RDN procedures were carried out by
the same experienced operator using the simplicity catheter
(Medtronic).
RESULTS 69 patients, mean age 56  9 year, were randomized for
RDN (n ¼ 36) or SHAM (n ¼ 33). One patient suffered a NSTEMI close to
randomization and was excluded. Groups showed similar demog-
raphy and baseline parameters. Mean baseline ASBP was 159 
12 mmHg (RDN) and 159  14 mmHg (SHAM). Groups had similar re-
ductions in ASBP compared to baseline at 3 months: - 6.2 
18.8 mmHg (RDN) vs. - 6.0  13.5 mmHg (SHAM) and at 6 months: - 6.1
 18.9 mmHg (RDN) vs. - 4.3  15.1 mmHg (SHAM). Mean antihyper-
tensive DDD usage at 3 month was equal 6.8  2.7 (RDN) vs. 7.0  2.5
(SHAM), although more RDN patients (41 %) had medical changes than
SHAM pt (24 %).
CONCLUSIONS Renal denervation performed at a single center and
by a high volume operator reduced ASBP to the same level as SHAM
treatment. This result is in line with ﬁndings from the HTN3 trial.
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BACKGROUND In this study we investigated whether multi-electrode
catheter-based renal sympathetic denervation (RDN) has favorable
effects on left ventricular (LV) structural and functional indices
in patients with resistant hypertension after a follow-up of 24
months.
METHODS Twenty patients with resistant hypertension [age: 5710
years, 13 males, ofﬁce blood pressure (BP): 182/9719/18 mmHg under
4.50.6 drugs] who underwent RDN were followed-up for 24 months.
A full transthoracic echocardiographic study was performed in all
patients and LV mass was calculated using the Devereux formula and
was indexed for body surface area and height.
RESULTS Average ofﬁce BP was reduced to 14821/8514 mmHg at 12
months and to 14323/8014 mmHg at 24 months (p<0.001 for all). In
the RDN group, LV mass index was signiﬁcantly reduced from
13620.1 g/m2 (56.58.7 g/m2.7) to 12116.6 g/m2 (50.66 g/m2.7) at
12 months and to 115.623.3 g/m2 (48.89.3 g/m2.7) at 24 months
(p<0.01 for allþ). RDN decreased mean interventricular septum
thickness from 12.11.2 mm to 11.40.9 mm at 12 months and to
11.30.9 mm at 24 months (p<0.05 for all). After RDN, the number of
patients with concentric LV hypertrophy (i.e. relative wall
thickness>0.42 and LV mass>48 g/m2.7 for male and >44 g/m2.7 for
female) decreased from 16 patients (80%) at baseline to 10 patients
(50%) at 12 months, and to 7 patients (36.8%) at 24 months. Regarding
diastolic function RDN caused an increase in mitral valve E΄/A΄ ratio
from 0.620.28 to 0.700.25 at 12 months and to 0.840.32 at 24
months (p<0.05 for all) and a decrease in the E/E΄ ratio from 14.86.1
to 11.83.7 at 12 months and to 9.74 (p<0.05 for all).
CONCLUSIONS This the ﬁrst study to show that multi-electrode RDN
system results in a signiﬁcant and sustained improvement of diastolic
function and attenuation of LV mass index in increased cardiovas-
cular risk resistant hypertensive patients after a follow-up of 24
months. These results suggest pleiotropic cardiovascular beneﬁts of
RDN therapy in the setting of resistant hypertension.
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